Columbia FIGURE 1 Change in hemoglobin, s-ferritin, and transferrin saturation over time by treatment group, full analysis set. CI: confidence interval
Iron isomaltoside is one of the newer IV iron formulations able to supply a complete replacement dose in a short, single visit in most patients.
Herein, we present data from a subpopulation of gynecology patients with IDA from a previously reported trial. 5 The objective was to compare the efficacy and safety of iron isomaltoside to iron sucrose in gynecology patients (corresponding to 48.5% of those in the larger trial) with IDA and who were intolerant of, or unresponsive to oral iron therapy or who would benefit from rapid iron repletion.
Patients were randomized 2:1 to iron isomaltoside (Monofer®, Pharmacosmos A/S, Holbaek, Denmark) or iron sucrose (Venofer®, Vifor Pharma, Glattbrugg, Switzerland). There were more responders in the iron isomaltoside group compared to the iron sucrose group. A risk difference of 13.9%-points in the FAS and 14.3%-points in the PP set as well as non-inferiority of iron isomaltoside to iron sucrose was observed.
A predetermined test for superiority was performed, confirming superiority of iron isomaltoside over iron sucrose (FAS: P 5 .033; PP: P 5 .031).
In the FAS, the largest increase in Hb from baseline to any time For both FAS and PP, the difference between iron isomaltoside and iron sucrose was statistically significant (P < .001).
Analysis of time to Hb increase 2 g/dL showed a statistically significantly shorter time to Hb increase 2 g/dL in the iron isomaltoside group compared with the iron sucrose group with a hazard ratio (HR) (95% CI) of 1.71 (0.19; 0.89) (P 5 .0026).
The change from baseline in Hb and TSAT was statistically significantly higher in the iron isomaltoside compared to the iron sucrose group at each time point (P .0005 and P .0001, respectively) ( Figure 1) , and s-ferritin was statistically significantly higher with iron isomaltoside at weeks 1 to 4 (P .002) (Figure 1 ).
In both treatment groups, the SF-36 scores in the eight health domains improved from baseline to weeks 2 and 5. There were no differences between the groups.
The ADR profiles in the treatment groups were similar to the ones observed in the main trial. In this trial, we evaluated the efficacy and safety of IV iron isomaltoside in comparison to iron sucrose in gynecological patients with IDA. The women were primarily pre-menopausal with a history of menorrhagia but were otherwise healthy.
For the primary endpoint, the proportion reaching a Hb increase from baseline of 2 g/dL at any time between week 1 and 5, both non-inferiority and superiority was confirmed for iron isomaltoside compared to iron sucrose. Furthermore, a significantly shorter time to
Hb increase 2 g/dL was observed with iron isomaltoside. For all biochemical efficacy parameters (Hb, s-ferritin, and TSAT) measured, more rapid and/or greater improvements were found with iron isomaltoside.
These findings are in agreement with results of the main trial. 5 QoL improved in both treatment groups during the trial. In a previous trial including women with postpartum hemorrhage, a single dose of iron isomaltoside led to statistically significant differences in fatigue and depression scores, as well as in hematological and iron parameters, all favoring iron isomaltoside when compared with standard medical care. 6 Treatment with iron isomaltoside and iron sucrose was generally well tolerated with <1% SARs.
In conclusion, iron isomaltoside was more effective than iron sucrose in ensuring a rapid improvement in Hb and other iron-related parameters. Larger doses of iron isomaltoside can be administered within a shorter time to achieve full iron correction. Iron isomaltoside administration was well tolerated in gynecological patients with IDA. Based on the HCT-CI scores, these patients were divided into low- 
